EE165 Cost-Effectiveness Analysis Model of Aspirin and Aspirin Combination Therapy in Acute Ischemic Stroke Patient in West Sumatera

Evaluating Economic Outcomes: Single-Use Aspirin vs. Aspirin-Clopidogrel in Ischemic Stroke Patients Based on Barthel Index Scores

“…In Fitriani's research (2021) it was stated that based on the calculation of the Incremental Cost-Effectiveness Ratio value for single aspirin therapy and the aspirinclopidogrel combination, the RIEB value was IDR (-).864,636 for the PT parameter and IDR (-).474,315 for the APTT parameter. So the results show that single aspirin therapy has better effectiveness and lower costs compared to the combination of aspirin-clopidogrel [10]. However, there are differences in several other previous studies, this is because the economy is always changing from time to time [25][26][27].…”

“…The effectiveness resulting from the use of the aspirin-clopidogrel combination group was greater than the effectiveness of the aspirin alone group. Based on the ICER value obtained, the ICER value is in the quadrant (quadrant 2), this can be interpreted as aspirin-clopidogrel combination antiplatelet therapy having (high effectiveness at low cost) [10].…”

“…Various clinical studies to compare the effectiveness of antiplatelet administration as a stroke prevention therapy have been carried out. Several studies have shown that single aspirin is more effective than clopidogrel [10,11]. Several trials have tested the efficacy and safety of clopidogrel and aspirin versus aspirin in preventing recurrent stroke in ischemic stroke [12][13][14].…”

“…In this Cost-Effectiveness Analysis, the total cost will be compared with the effects of two or more treatment options [24]. The aim is to assist in analyzing rational therapy selection decision-making and evaluating the economic impact of using combined and single antiplatelets in ischemic stroke patients [10]. So we get a therapy that has better cost effectiveness for ischemic stroke patients.…”